Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Whi Parren

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Immunology|April 17, 2016
Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?Janine Schuurman, Paul Whi Parren
Current Opinion in Immunology|July 8, 2008
An integrated science-based approach to drug developmentPaul Whi Parren, Jan G J van de Winkel
Current Opinion in Immunology|October 30, 2025
Local complement inhibition by selective precision-targeted therapiesHaiyu Wang, Daan J van den Brink, Balthasar A Heesters, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activityOdd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.
Mabs|June 4, 2015
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationEwald T J van den Bremer, Frank J Beurskens, Marleen Voorhorst, et al.
JCI Insight|October 11, 2019
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancerLouise A Koopman, Mikkel G Terp, Gijs G Zom, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Immunology|April 17, 2016
Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?Janine Schuurman, Paul Whi Parren
Current Opinion in Immunology|July 8, 2008
An integrated science-based approach to drug developmentPaul Whi Parren, Jan G J van de Winkel
Current Opinion in Immunology|October 30, 2025
Local complement inhibition by selective precision-targeted therapiesHaiyu Wang, Daan J van den Brink, Balthasar A Heesters, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activityOdd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.
Mabs|June 4, 2015
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationEwald T J van den Bremer, Frank J Beurskens, Marleen Voorhorst, et al.
JCI Insight|October 11, 2019
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancerLouise A Koopman, Mikkel G Terp, Gijs G Zom, et al.
Pageof 1